Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.49 |
| ▸ | PARP1 | P09874 | 5/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365567 | 0.82 | BRD4 (0.39) | BRD4PARP1NR1H2HTTALDH1A1 | |
| SCHEMBL12365544 | 0.82 | BRD4 (0.39) | BRD4PARP1NR1H2ALDH1A1CHEK1 | |
| SCHEMBL21190842 | 0.82 | BRD4 (0.50) | BRD4PARP1NR1H2HTTALDH1A1 | |
| SCHEMBL12365546 | 0.80 | BRD4 (0.40) | BRD4PARP1NR1H2ALDH1A1 | |
| SCHEMBL13695404 | 0.78 | KDM4E (0.42) | BRD4NR1H2ALDH1A1KDM4EGAA | |
| SCHEMBL13695411 | 0.78 | NR1H2 (0.38) | BRD4NR1H2ALDH1A1KDM4EGAA | |
| SCHEMBL13695403 | 0.78 | BRD4 (0.36) | BRD4PARP1NR1H2 | |
| SCHEMBL13695358 | 0.77 | KDM4E (0.41) | BRD4PARP1HTTALDH1A1KDM4E | |
| SCHEMBL13695405 | 0.75 | BRD4 (0.39) | BRD4NR1H2HTTALDH1A1KDM4E | |
| SCHEMBL13695402 | 0.75 | BRD4 (0.37) | BRD4NR1H2ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948454-B1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) | 2017-05-31 | — | — | EP | disclosed |
| US-9447105-B2 | Triazine compounds and a process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-09-20 | — | — | US | disclosed |
| US-9447105-B2 | Triazine compounds and a process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-09-20 | — | — | US | disclosed |
| US-9447105-B2 | Triazine compounds and a process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-09-20 | — | — | US | disclosed |
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-12-10 | — | — | US | disclosed |
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-12-10 | — | — | US | disclosed |
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-12-10 | — | — | US | disclosed |
| US-9006713-B2 | Organic light-emitting display apparatus | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-04-14 | — | — | US | disclosed |
| WO-2014115171-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-07-31 | — | — | WO | disclosed |
| EP-1669071-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7244733-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7112675-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1669071-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1183033-B1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-6982265-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-01-03 | — | — | US | disclosed |
| EP-1183033-A4 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1183033-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071129-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | TPH2, IDO2, INMT | BRD4 984/4885PARP1 883/4885NR1H2 3623/4885 |
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | BRD4 729/4885PARP1 677/4885NR1H2 3177/4885 |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | BRD4 729/4885PARP1 677/4885NR1H2 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.